首页> Oral oncology> Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.

Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.

导出 LinkOut

翻译打印收藏纠错

第一作者： Anna,Yuan

第一单位： Division of Oral Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA 02115, USA. Electronic address: annayuan@post.harvard.edu.

作者： Anna,Yuan ^[1] ; Sharyn L,Kurtz ^[2] ; Constance M,Barysauskas ^[3] ; Amy P,Pilotte ^[4] ; Andrew J,Wagner ^[5] ; Nathaniel S,Treister ^[6]

作者单位： Division of Oral Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA 02115, USA. Electronic address: annayuan@post.harvard.edu. ^[1] Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. ^[2] Department of Biostatistics and Computational Biology, 450 Brookline Avenue, Dana-Farber Cancer Institute, Boston, MA 02215, USA. ^[3] Department of Medical Oncology, Rhode Island Hospital Comprehensive Cancer Center, 1454 South County Trail, Suite 2100, East Greenwich, RI 02818, USA. ^[4] Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. ^[5] Division of Oral Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA 02115, USA. ^[6]

关键词 Mucositis Oral adverse events Oral complications Oral dysesthesia Oral toxicities Stomatitis Sunitinib Sutent Targeted cancer therapy Tyrosine kinase inhibitors